Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (ASD)

NCT05555615 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT05555615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05555615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (ASD)
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
November 2, 2022
Completion date
February 14, 2025
Enrollment
209 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

irritability associated with autism spectrum disorder